Is Bioasis Technologies Inc. (BTI.V) a Buy, Sell, or Hold?
Bioasis Technologies Inc.
TSXV:BTI.V
$0.005 CAD
$0 (0.0%)
- Volume
- 814
- Average Volume
- 95
- Market Capitalization
- $397.07K
- P/E Ratio
- -0.12
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.01
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.70
Industry, Sector & symbol
| Stock Exchange | TSXV |
| CEO | Deborah Ann Rathjen FTSE, |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BTI.V |
| CUSIP | None |
| CIK | None |
| Web | https://www.bioasis.us |
| Phone | 203 533 7082 |
| Currency | CAD |
| Employees | None |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.99 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.70 |
| Quick Ratio | 0.70 |
| Cash Ratio | 0.58 |
Sales & Book Value
| Annual Sales | $37725 |
| Price / Sales | 10.53 |
| Cash Flow | -0.05 |
| Price / Cash Flow | -0.11 |
| Price / Book | -0.19 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.041 |
| Trailing P/E Ratio | -0.12 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-2.96M |
| Net Margin | -7846.50% |
| Pretax Margin | -7846.50% |
| Return on Equity | 392.02% |
| Return on Assets | -130.64% |
Financials Score
| AltmanZ Score | -42.13 |
| Piotroski Score | 2.00 |
| Working Capital | -3.22M |
| Total Assets | 1.76M |
| Ebit | -3.22M |
| Market Cap | 397.07K |
| Total Liabilities | 4.46M |
Poll Results
About Bioasis Technologies Inc. (TSXV:BTI.V) Stock
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also establishe ... d numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Frequently Asked Questions
-
What is the current Bioasis Technologies Inc. (BTI.V) stock price?
-
Bioasis Technologies Inc.(TSXV:BTI.V) stock price is $0.005 in the last trading session. During the trading session, BTI.V stock reached the peak price of $0.01 while $0.005 was the lowest point it dropped to. The percentage change in BTI.V stock occurred in the recent session was 0.0% while the dollar amount for the price change in BTI.V stock was $0.
-
BTI.V's industry and sector of operation?
-
The TSXV listed BTI.V is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BTI.V?
-
Mei Mei Tian | Vice President & Head of External Research
Aaron Elton | Director of Marketing
David Jenkins | Chief Financial Officer
Graeme Dick | Director of Investor Relations
Deborah Ann Rathjen | Executive Chairman, Chief Executive Officer & President -
How many employees does BTI.V have?
-
Number of BTI.V employees currently stands at None. BTI.V operates from 157 Church Street, New Haven, CT 06510, US.
-
Link for BTI.V official website?
-
Official Website of BTI.V is: https://www.bioasis.us
-
How do I contact BTI.V?
-
BTI.V could be contacted at phone #203 533 7082 and can also be accessed through its website. BTI.V operates from 157 Church Street, New Haven, CT 06510, US.
-
How many shares of BTI.V are traded daily?
-
The average number of BTI.V shares traded daily for last 3 months was 95.
-
What is the market cap of BTI.V currently?
-
The market value of BTI.V currently stands at $397.07K with its latest stock price at $0.005